ZD-1611 manufacturers
- ZD-1611
-
- $2500.00
-
2026-07-27
- CAS:186497-38-1
- Purity:
- Supply Ability: 10g
|
| | ZD-1611 Basic information |
| Product Name: | ZD-1611 | | Synonyms: | ZD-1611;Benzenepropanoic acid, 4-[3-[[(3-methoxy-5-methyl-2-pyrazinyl)amino]sulfonyl]-2-pyridinyl]-α,α-dimethyl-;ZD 1611,ZD1611 | | CAS: | 186497-38-1 | | MF: | C22H24N4O5S | | MW: | 456.52 | | EINECS: | | | Product Categories: | | | Mol File: | 186497-38-1.mol |  |
| | ZD-1611 Chemical Properties |
| Boiling point | 653.9±65.0 °C(Predicted) | | density | 1.339±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 4.62±0.13(Predicted) |
| | ZD-1611 Usage And Synthesis |
| Uses | ZD-1611 is a potent, orally active, selective ETA receptor antagonist, used for the research of ischemic stroke. | | in vivo | ZD1611 (0.3 mg/kg, p.o.) has a duration of action of more than 7 h in rats. In the dog, ZD1611 is active for at least 6 h at dose of 0.6 mg/kg p.o[1]. ZD1611 (0.15 mg/kg/day) in combination with candesartan decreases the brain damage and improves the neurological scores in rats. However, ZD1611 or candesartan alone does not significantly decrease the brain damage or improve neurological scores[2]. | | IC 50 | ETA | | References | [1] Wilson C, et al. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1999 Sep;290(3):1085-91. PMID:10454481
[2] Stenman E, et al. Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat. Eur J Pharmacol. 2007 Sep 10;570(1-3):142-8. Epub 2007 Jun 9. DOI:10.1016/j.ejphar.2007.05.049 |
| | ZD-1611 Preparation Products And Raw materials |
|